What You Need to Know About Esbriet

What You Need to Know About Esbriet

Esbriet (pirfenidone), is an anti-fibrotic drug used in the treatment of patients with mild to moderate idiopathic pulmonary fibrosis (IPF). It’s made by the pharmaceutical company, Genentech. Find out more about Esbriet for treating idiopathic pulmonary fibrosis. A study by researchers at the University of Wisconsin found that…

American Lung Association Initiative for Healthy Air

Healthy Air is an initiative run by the American Lung Association (ALA) that aims to education people on how to improve the air they breathe, avoid pollution and help influence public policy to improve the air quality. MORE: Four ways the American Lung Association helps patients manage their lung disease.

Holding Tight to What’s Positive Up Ahead

Throughout this yearlong journey with idiopathic pulmonary fibrosis (IPF), to which I am an unwilling participant, I have often spoken with others about the benefits of having something positive to look forward to. Knowing something good is on the horizon helps in coping with this disease — whether…

What a Doctor Wants People to Know About Chronic Illnesses

Having a chronic illness presents many challenges for patients, not only in terms of managing the symptoms they suffer but also having to deal with people’s preconceived ideas about invisible illnesses. MORE: Did you know that pulmonary fibrosis can be difficult to diagnose and treat?  Dr. Amy Stenehjem spent much of…

Esbriet Equals Prednisone and Tops Acetylcysteine as Treatment for Pulmonary Fibrosis in Rats

Esbriet (pirfenidone) was as effective as prednisone and better than acetylcysteine at inhibiting inflammation and fibrosis in the lungs of rats with idiopathic pulmonary fibrosis (IPF), according to a study. The research, “Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models,” was…